# BLI1100-202: BLI1100 for the Treatment of Moderate to Severe Acne Vulgaris

> **NCT01815450** · PHASE2 · COMPLETED · sponsor: **Braintree Laboratories** · enrollment: 369 (actual)

## Conditions studied

- Acne Vulgaris

## Interventions

- **DRUG:** BLI1100
- **DRUG:** BLI1100 - modified formulation
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01815450
- **Lead sponsor:** Braintree Laboratories
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02
- **Primary completion:** 2013-11
- **Final completion:** —
- **Target enrollment:** 369 (ACTUAL)
- **Last updated:** 2015-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01815450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01815450, "BLI1100-202: BLI1100 for the Treatment of Moderate to Severe Acne Vulgaris". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01815450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*